J. Goldman & Co’s Pliant Therapeutics PLRX Stock Holding History

J. Goldman & Co’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-39,591	Closed	-$765K	–	455
2022 Q4	$765K	Buy	+39,591	New	+$828K	0.04%	241

Other funds holding PLRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

J. Goldman & Co's PLRX Position: Q1 2023 in Review

J. Goldman & Co sold out of Pliant Therapeutics (PLRX) in Q1 2023, closing a stake of 39,591 shares — an estimated $765K sold.

J. Goldman & Co first reported a position in PLRX in Q4 2022 and held it in 1 quarter. The position peaked at $765K in Q4 2022. 143 funds tracked by Wall St. Rank hold PLRX as of Q1 2023.

J. Goldman & Co reported no remaining Pliant Therapeutics position as of Q1 2023 after selling out during the quarter.
J. Goldman & Co sold 39,591 Pliant Therapeutics shares in Q1 2023, an estimated $765K.
J. Goldman & Co first reported a position in Pliant Therapeutics in Q4 2022 and held it in 1 quarter.
J. Goldman & Co's Pliant Therapeutics position peaked at $765K in Q4 2022.
143 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2023.

Based on J. Goldman & Co's 13F filing for Q1 2023, filed 15 May 2023.